Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg After 1 Week of Treatment Withdrawal

PHASE4CompletedINTERVENTIONAL
Enrollment

822

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Hypertension
Interventions
DRUG

Aliskiren

Aliskiren 150 mg tablets taken orally daily. 1 tablet for the first two weeks followed by 2 tablets for 10 weeks.

DRUG

Telmisartan

Telmisartan 40 mg capsules taken orally daily. 1 capsule the first 2 weeks followed by 2 capsules for 10 weeks.

DRUG

Placebo to Aliskiren

Placebo to Aliskiren tablets taken orally daily. 1 Tablet for the first 2 weeks and 2 tablets during the no treatment (withdrawal) week.

DRUG

Placebo to Telmisartan

Placebo to Telmisartan capsule taken orally daily. 1 capsule for the first 2 weeks and 2 capsules during the no treatment (withdrawal) week.

Trial Locations (16)

Unknown

Investigative Site, Sorocaba

Investigative Site, Gatineau

Investigative Site, Guayaquil

Investigative Site, Erfurt

Invesitagtive Site, Budapest

Investigative Site, Kuala Lumpur

Investigative Site, Mexico City

Investigative Site, Panama City

Investigative Site, Manila

Investigative Site, Singapore

Investigative Site, Bratislava

Investigative Site, Cheongju-si

Investigative Site, Seville

Investigative Site, Istanbul

Investigative Site, Westbury

Investigative Site, Caracas

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00865020 - Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg After 1 Week of Treatment Withdrawal | Biotech Hunter | Biotech Hunter